GeneDx Holdings
WGS

GeneDx Holdings (WGS) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
GuggenheimMaintainedBuy$83.00 from $74.00Oct 1, 2026
BTIGMaintainedBuy$90.00Aug 4, 2026
Canaccord GenuityMaintainedBuy$90.00 from $75.00Aug 4, 2026
GuggenheimMaintainedBuy$74.00 from $70.00Jun 29, 2026
Piper SandlerMaintainedOverweight$63.00 from $50.00Jun 23, 2026
BTIGMaintainedBuy$90.00 from $170.00May 5, 2026
GuggenheimMaintainedBuy$70.00 from $100.00May 5, 2026
Wells FargoMaintainedOverweight$75.00 from $155.00May 5, 2026
Canaccord GenuityMaintainedBuy$75.00 from $100.00May 5, 2026
Canaccord GenuityMaintainedBuy$100.00 from $170.00Apr 20, 2026
GuggenheimMaintainedBuy$100.00 from $170.00Mar 30, 2026
BTIGMaintainedBuy$170.00 from $200.00Feb 24, 2026
Piper SandlerMaintainedOverweight$130.00 from $160.00Feb 24, 2026
Wells FargoUpgradedEqual-Weight → Overweight$155.00Feb 9, 2026
Canaccord GenuityMaintainedBuy$170.00 from $160.00Dec 22, 2025
Wells FargoMaintainedEqual-Weight$155.00 from $140.00Dec 15, 2025
BTIGMaintainedBuy$200.00 from $165.00Dec 12, 2025
Wells FargoMaintainedEqual-Weight$140.00 from $95.00Nov 4, 2025
BTIGMaintainedBuy$165.00 from $140.00Oct 29, 2025
GuggenheimMaintainedBuy$170.00 from $115.00Oct 29, 2025

Frequently asked questions

  • What is the latest analyst rating on WGS?

    On Oct 1, 2026, Guggenheim maintained GeneDx Holdings at Buy with a price target of $83.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.